Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life
- PMID:14621276
- DOI:10.1080/00365520310004524
Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life
Abstract
Background:Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are intestinal diseases perceived differently by patients and doctors: the former is considered essentially as an 'organic' disease (i.e. an illness in which the role of stress or psychological factors is at best secondary to the disease itself), whereas the latter is acknowledged as a 'functional' disorder (i.e. illness thought to be more in the 'mind' than in the body of the patient). Accordingly, the respective impact of the two diseases on patients' health-related quality of life (HRQOL) is perceived to be very different. We aimed to compare the relative impact of the disease on HRQOL, psychological profile and perceived burden of stressful life events in two groups of outpatients suffering from IBS and IBD and attending our outpatient department at an Italian university hospital. Eighty patients with IBD (26 with ulcerative colitis and 54 with Crohn disease) and 85 controls with IBS formed the patient samples of the study.
Methods:Three questionnaires were given to the patients while they were attending the outpatient department because of their previously diagnosed disease, namely the SF-36 (a generic well-validated tool for measuring HRQOL), the SCL-90 (for assessing the psychological profile of patients), and the Holmes & Rahe schedule (for the assessment of stressful life experiences). The results were then compared by means of analysis of variance (ANOVA) and Bonferroni-adjusted t test, when appropriate.
Results:HRQOL appeared to be similarly reduced in both disease groups (SF-36 overall mean value: 58.2 +/- 16.1 in IBS patients versus 56.4 +/- 22.3 in IBD patients: P > 0.05) in comparison with normative Italian data. Furthermore, the overall severity of psychological symptoms was not statistically different between patients suffering from IBD versus IBS, as shown by SCL-90 mean scores of 0.89 + 0.45 versus 0.83 +/- 0.48, respectively (P > 0.05). On the contrary, the severity of recent stressful life experiences was perceived to be higher by IBS than by IBD patients (mean SRE score: 110.8 = 110.2 versus 61.6 +/- 78.8; P < 0.05).
Conclusion:我们的研究支持的观点,至少在再保险ferral centres, patients with IBS show health-related quality of life, psychological distress and recent occurrence of stressful life events of severity at least comparable with age-matched IBD patients.
Similar articles
-
The central role of psychopathology and its association with disease severity in inflammatory bowel disease and irritable bowel syndrome.Riv Psichiatr. 2019 Mar-Apr;54(2):75-83. doi: 10.1708/3142.31248. Riv Psichiatr. 2019. PMID:30985832
-
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis.Am J Gastroenterol. 2012 Mar;107(3):451-9. doi: 10.1038/ajg.2011.377. Epub 2011 Nov 15. Am J Gastroenterol. 2012. PMID:22085819 Free PMC article.
-
Differences in the health-related quality of life, affective status, and personality between irritable bowel syndrome and inflammatory bowel disease patients.Eur J Gastroenterol Hepatol. 2010 Jul;22(7):862-7. doi: 10.1097/MEG.0b013e3283307c75. Eur J Gastroenterol Hepatol. 2010. PMID:19701092
-
Inflammatory bowel disease and irritable bowel syndrome: similarities and differences.当今杂志。2014;30(4):352 - 8。doi: 10.1097/MOG.0000000000000070. Curr Opin Gastroenterol. 2014. PMID:24811054 Review.
-
Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550. Health Technol Assess. 2013. PMID:24286461 Free PMC article. Review.
Cited by
-
Impact of Work Hours on the Quality of Life of Adult Employees With Irritable Bowel Syndrome in Saudi Arabia.Cureus. 2022 Nov 28;14(11):e31983. doi: 10.7759/cureus.31983. eCollection 2022 Nov. Cureus. 2022. PMID:36589167 Free PMC article.
-
Epidemiology of irritable bowel syndrome in hospitalized patients with inflammatory bowel disease: Nationwide Inpatient Sample analysis from 2007-2016.Ann Gastroenterol. 2022 Nov-Dec;35(6):603-608. doi: 10.20524/aog.2022.0754. Epub 2022 Oct 17. Ann Gastroenterol. 2022. PMID:36406967 Free PMC article.
-
Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome.Neurogastroenterol Motil. 2023 Feb;35(2):e14483. doi: 10.1111/nmo.14483. Epub 2022 Sep 30. Neurogastroenterol Motil. 2023. PMID:36178331 Free PMC article.
-
Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.Trials. 2022 Jul 8;23(1):552. doi: 10.1186/s13063-022-06492-6. Trials. 2022. PMID:35804433 Free PMC article.
-
Impact of Rome IV irritable bowel syndrome on work and activities of daily living.Aliment Pharmacol Ther. 2022 Sep;56(5):844-856. doi: 10.1111/apt.17132. Epub 2022 Jul 6. Aliment Pharmacol Ther. 2022. PMID:35794733 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous